The study finds that COVID-19 vaccination can significantly reduce symptoms and improve well-being in patients suffering from post-COVID-19 conditions (PCC). Vaccination also lowered systemic markers of inflammation but did not entirely eliminate persistent SARS-CoV-2 antigens, which may continue to contribute to inflammation.
J&J’s major depressive disorder drug hits endpoints in Phase 3 trial
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
May 30, 2024